OncoSec Medical Inc (ONCSQ)

[hschlauch]

The slide you are referencing is exclusive to those patients who observed responses to the TAVO+Pembro combination; it omits patients who were previously treated with an anti-pd-1 agent and failed the TAVO+Pembro combo. I believe a total of 10 patients were actual anti-pd-1 failures prior to the TAVO+Pembro combo. This suggests a response rate of 20%. I wouldn't lump prior anti-ctla-4 monotherapy and Tvec failures just because they are immunotherapies - they have completely different immunological mechanics. Moreover, PISCES is exclusive to anti-pd-1 failures.

Something we have to remember though with the patient population in OMS-I102... these patients were immunologically cold at baseline, meaning relatively few CD8 T cells. Not all anti-pd-1 non-responders will be so frozen, immunologically speaking, at baseline. In other words, the odds of response success in the PISCES trial should be better than the OMS-I102 predicted non-responder trial.